Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). (Q43430617)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2004

Language	Label	Description	Also known as
English	Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).	scientific article published in June 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

0 references

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

author name string

C-M Wendtner

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

M Ritgen

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C D Schweighofer

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

G Fingerle-Rowson

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

H Campe

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

G Jäger

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

B Eichhorst

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

R Busch

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

H Diem

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

A Engert

10

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S Stilgenbauer

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

H Döhner

12

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

M Kneba

13

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

B Emmerich

14

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

M Hallek

15

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

German CLL Study Group (GCLLSG)

16

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

publication date

1 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1093-1101

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

T-cell epitope mapping by flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Infectious complications in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Bone marrow biopsy in hemophagocytic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Pharmacokinetics of CAMPATH-1H: assay development and validation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

21 January 2018

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural motifs involved in human IgG antibody effector functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403354

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403354

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43430617&oldid=2206033220"